Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 4,245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Pachyonychia Congenita
Interventions: 1% sirolimus cream (TD201 1%); Drug
Lead sponsor: TransDerm, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Onychomycosis
Interventions: TDT067, Placebo, Transfersome; Drug
Lead sponsor: Celtic Pharma Development Services; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Albequerque, New Mexico

Conditions: Type 2 Diabetes Mellitus
Interventions: KD026, Placebo, Metformin; Drug
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • West Hills, California + 6 more

Conditions: Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions: VE303, Placebo; Drug
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more

Conditions: Prostate Cancer
Interventions: Dendritic cell immunotherapy; Drug
Lead sponsor: Northwest Biotherapeutics; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Springdale, Arkansas • Los Angeles, California • San Diego, California + 13 more

Conditions: HIV-1 Infection
Interventions: Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: 400 µg Brimonidine Implant, Sham; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 55 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more

Conditions: Obstetric Labour, Premature
Interventions: GSK221149A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 32
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: Contraception
Interventions: Norgestrel 0.075 mg tablets; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Homewood, Alabama • McCalla, Alabama + 38 more

Conditions: Hyperkalemia, Chronic Kidney Disease, Kidney Dysfunction
Interventions: Zirconium silicate (ZS), Placebo; Drug
Lead sponsor: ZS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Tempe, Arizona • Costa Mesa, California • Edgewater, Florida + 6 more

Conditions: Healthy Volunteers
Interventions: Saccharomyces boulardii, Amoxicillin Clavulanate; Dietary Supplement · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastrointestinal Stromal Tumor
Interventions: Placebo, SU011248; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 27
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 20 more

Conditions: Bipolar Disorder
Interventions: Riluzole, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: PSD502; Drug
Lead sponsor: Plethora Solutions Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 4,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more

Conditions: Sunscreening Agents
Interventions: CAP Unscented; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Drug Abuse
Interventions: Istradefylline, Phentermine 45 mg, Placebo; Drug · Other
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tobacco Use Disorder
Interventions: Brief Negotiated Interview (BNI), Nicotine replacement therapy (NRT), CT Smokers Quitline (QL), SmokefreeText (Text); Behavioral · Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pruritus, Burns
Interventions: Serlopitant, Placebo; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 4 more

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more

Conditions: Malaria
Interventions: AQ-13, Chloroquine (CQ) Treatment; Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 21 Years to 45 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

TDT 067 Onychomycosis Study

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

A Study of Oral Contraception Under Simulated OTC Conditions

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota

A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)

A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression

Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Clinical Study to Evaluate the Efficacy of an Over-the-counter (OTC) Sunscreen Lip Balm Product

A Study to Evaluate Abuse Potential of Istradefylline

Optimizing Tobacco Dependence Treatment in the Emergency Department

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine